(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 September 2022 (22.09.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/197901 A1

(51) International Patent Classification:
A61K 45/06 (2006.01) *A61P 25/24* (2006.01)
A61K 9/00 (2006.01) *A61K 31/58* (2006.01)

(21) International Application Number:
PCT/US2022/020716

(22) International Filing Date:
17 March 2022 (17.03.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/162,501 17 March 2021 (17.03.2021) US
63/284,592 30 November 2021 (30.11.2021) US

(71) Applicant: **SAGE THERAPEUTICS, INC.** [US/US]; 215 First Street, Cambridge, MA 02142 (US).

(72) Inventors: **LASSER, Robert, Alfonso**; 215 First Street, Cambridge, MA 02142 (US). **DOHERTY, James**; 215 First Street, Cambridge, MA 02142 (US). **JONAS, Jeffrey, Martin**; 215 First Street, Cambridge, MA 02142 (US). **KANES, Stephen, Jay**; 215 First Street, Cambridge, MA 02142 (US). **GUNDUZ-BRUCE, Handan**; 215 First Street, Cambridge, MA 02142 (US). **DUNBAR, Joi, Lisa**; 215 First Street, Cambridge, MA 02142 (US). **ADIWI-JAYA, Bambang, Senoaji**; 215 First Street, Cambridge, MA 02142 (US).

(74) Agent: **DOYLE, Kathryn, D.**; Honigman LLP, 650 Trade Centre Way, Suite 200, Kalamazoo, MI 49002 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2022/197901 A1

(54) Title: A 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

(57) Abstract: The present disclosure relates to methods of treating major depressive disorder (MDD) in a subject in need thereof by (i) performing an initial treatment course on the subject comprising administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof, and (ii) performing 0, 1, or 2 subsequent treatment courses on the subject, wherein each subsequent treatment course comprises administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof, in response to a recurrence of depression symptoms. The 0, 1, or 2 subsequent treatment courses can be performed over a period of 12 months from the beginning of the initial treatment course.